Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Increases By 184.8%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 214,479 shares, an increase of 184.8% from the February 26th total of 75,311 shares. Based on an average trading volume of 6,222,165 shares, the days-to-cover ratio is presently 0.0 days. Currently, 13.1% of the company’s stock are sold short.

Catheter Precision Price Performance

NYSEAMERICAN VTAK traded down $0.02 during mid-day trading on Friday, reaching $1.09. 67,602 shares of the company’s stock traded hands, compared to its average volume of 1,144,281. Catheter Precision has a 1-year low of $1.05 and a 1-year high of $15.68. The company has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $2.07. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.46 and a quick ratio of 0.46.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent quarter. 20.34% of the stock is currently owned by hedge funds and other institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.